|Mr. Nick Leschly||Pres, CEO & Director||814.62k||732.07k||1973|
|Mr. Jeffrey T. Walsh||Chief Financial & Strategy Officer and Treasurer||568.05k||N/A||1966|
|Ms. Susanna Gatti High||Chief Operating Officer||16.63k||N/A||1968|
|Dr. Philip D. Gregory D. Phil.||Chief Scientific Officer||622.15k||N/A||1971|
|Dr. David M. Davidson M.D.||Chief Medical Officer||554.35k||299.61k||1964|
bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease. The company's lead product candidates in oncology include bb2121 and bb21217, which are anti- B-cell maturation antigens in Phase I clinical trials for the treatment of relapsed/refractory multiple myeloma. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology. It also has collaborations with Medigene AG for the research and development of T cell receptor product candidates directed against antigens for the treatment of cancer indications; and TC BioPharm Limited to research and develop gamma delta chimeric antigen receptor modified T cell product candidates for cancer immunotherapy. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.
bluebird bio, Inc.’s ISS Governance QualityScore as of March 1, 2018 is 4. The pillar scores are Audit: 1; Board: 2; Shareholder Rights: 6; Compensation: 6.